Novartis Korea to expand free coverage for Lucentis

Published: 2008-07-07 06:51:00

Updated: 2008-07-07 06:51:00

Novartis Korea says it has expanded the scope of its patient assistance program for Lucentis (ranibizumab injection) for the treatment of neovascular (wet) age-related macular degeneration (AMD).

The company plans to provide more expanded assistance to eligible patients who cannot access neede...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK